---
layout: default
title: Hydroxyurea
description: "Hydroxyurea çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 83
evidence_level: L2
indication_count: 10
---

# Hydroxyurea

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Hydroxyureaï¼šå¾è¡€æ¶²è…«ç˜¤åˆ°å¥³æ€§ä¹³è…ºç™Œ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Hydroxyurea å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Hydroxyurea åŸæœ¬ç”¨æ–¼æ²»ç™‚æ…¢æ€§éª¨é«“æ€§ç™½è¡€ç—…ã€éª¨é«“çº–ç¶­åŒ–åŠçœŸæ€§ç´…è¡€çƒå¢å¤šç—‡ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¥³æ€§ä¹³è…ºç™Œ (female breast carcinoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **è¶…é 20 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹ç ”ç©¶æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ…¢æ€§éª¨é«“æ€§ç™½è¡€ç—…ã€éª¨é«“çº–ç¶­åŒ–ã€çœŸæ€§ç´…è¡€çƒå¢å¤šç—‡ã€åµå·¢ç™Œã€é ­é ¸ç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å¥³æ€§ä¹³è…ºç™Œã€primary non-gestational choriocarcinoma of ovaryã€sickle cell-hemoglobin E disease syndromeã€sickle cell-hemoglobin c disease syndromeã€hereditary persistence of fetal hemoglobin-sickle cell disease syndromeã€sickle cell-hemoglobin d disease syndromeã€sickle cell-beta-thalassemia disease syndromeã€hereditary breast ovarian cancer syndromeã€ovarian mucinous adenocarcinomaã€ovarian clear cell adenocarcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.97% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | æœ‰æ•ˆè¨±å¯è­‰ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.97%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Hydroxyurea æ˜¯ä¸€ç¨®æ ¸ç³–æ ¸è‹·é…¸é‚„åŸé…¶æŠ‘åˆ¶åŠ‘ï¼Œé€éé˜»æ–· DNA åˆæˆç™¼æ®æŠ—è…«ç˜¤ä½œç”¨ã€‚
å®ƒå¯ä»¥æŠ‘åˆ¶ç´°èƒå¾ G1 æœŸé€²å…¥ S æœŸï¼Œä¸¦å¢åŠ ç´°èƒå°æ”¾å°„ç·šçš„æ•æ„Ÿæ€§ã€‚

**é æ¸¬åˆç†æ€§åˆ†æï¼š**
- Hydroxyurea å·²æ ¸å‡†ç”¨æ–¼å¤šç¨®å¯¦é«”è…«ç˜¤ï¼ˆåµå·¢ç™Œã€é ­é ¸ç™Œï¼‰
- åœ¨ä¹³ç™Œçš„é«˜åŠ‘é‡åŒ–ç™‚æ–¹æ¡ˆä¸­å·²æœ‰ä½¿ç”¨ç¶“é©—
- å¯ä½œç‚ºæ”¾å°„å¢æ•åŠ‘ï¼Œèˆ‡æ”¾å°„æ²»ç™‚åˆä½µä½¿ç”¨
- ç ”ç©¶é¡¯ç¤ºå¯èˆ‡å…¶ä»–è—¥ç‰©ï¼ˆå¦‚ valproic acidï¼‰ç”¢ç”Ÿå”åŒä½œç”¨

**æ©Ÿè½‰æ”¯æŒï¼š**
- æŠ‘åˆ¶ DNA åˆæˆå’Œä¿®å¾©
- èª˜å°è¤‡è£½å£“åŠ›ï¼Œå¢åŠ  DNA é›™è‚¡æ–·è£‚
- èˆ‡ valproic acid åˆä½µå¯æŠ‘åˆ¶åŒæºé‡çµ„ä¿®å¾©ï¼ˆPMID: 28837865ï¼‰
- è„‚è³ªè—¥ç‰©è¤‡åˆé«”å¯æé«˜ç´°èƒæ”å–ç‡ï¼ˆPMID: 38211596ï¼‰

### è‡¨åºŠè©¦é©—

æ–‡ç»ä¸­å ±å‘Šçš„è‡¨åºŠç¶“é©—åŒ…æ‹¬ï¼š

| ç ”ç©¶é¡å‹ | å¹´ä»½ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|---------|
| Phase I | 1991 | Am J Clin Oncol | FU-LV-HU çµ„åˆæ–¹æ¡ˆåœ¨æ™šæœŸä¹³ç™Œä¸­çš„ Phase I è©¦é©— |
| Phase I/II | 1994 | Bone Marrow Transplant | é«˜åŠ‘é‡ CY-Thiotepa-HU é…åˆè‡ªé«”å¹¹ç´°èƒç§»æ¤ç”¨æ–¼è½‰ç§»æ€§ä¹³ç™Œ |
| Phase I | 1992 | Cancer Chemother Pharmacol | 5-FUã€LVã€HU èˆ‡ cisplatin åˆä½µæ”¾ç™‚çš„è‡¨åºŠè—¥ç†å­¸ç ”ç©¶ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [38211596](https://pubmed.ncbi.nlm.nih.gov/38211596/) | 2024 | é›»è…¦æ¨¡æ“¬ | Drug Res | HU è„‚è³ªè—¥ç‰©è¤‡åˆé«”è¨­è¨ˆï¼Œé¶å‘ PI3K/AKT/mTOR é€šè·¯ |
| [28837865](https://pubmed.ncbi.nlm.nih.gov/28837865/) | 2017 | é«”å¤–ç ”ç©¶ | DNA Repair | Valproic acid å¢æ•ä¹³ç™Œç´°èƒå° HU çš„åæ‡‰ |
| [32795962](https://pubmed.ncbi.nlm.nih.gov/32795962/) | 2020 | é«”å¤–ç ”ç©¶ | DNA Repair | 2-hexyl-4-pentynoic acid èˆ‡ HU è¯åˆæŠ‘åˆ¶ä¹³ç™Œ |
| [7914447](https://pubmed.ncbi.nlm.nih.gov/7914447/) | 1994 | Phase I/II | Bone Marrow Transplant | é«˜åŠ‘é‡ CY-Thiotepa-HU ç”¨æ–¼è½‰ç§»æ€§ä¹³ç™Œçš„éå›ºæ²»ç™‚ |
| [21730979](https://pubmed.ncbi.nlm.nih.gov/21730979/) | 2011 | é«”å¤–ç ”ç©¶ | Br J Cancer | ATR æŠ‘åˆ¶åŠ‘èˆ‡ HU åœ¨ä¹³ç™Œå’Œåµå·¢ç™Œç´°èƒä¸­çš„æ•ˆæœ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. sickle cell-hemoglobin E disease syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.67%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. sickle cell-hemoglobin c disease syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.67%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. hereditary persistence of fetal hemoglobin-sickle cell disease syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.67%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. sickle cell-hemoglobin d disease syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.67%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. sickle cell-beta-thalassemia disease syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.67%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. cervical adenosarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.40%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.40%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. colon mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.32%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.32%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. rectum mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.31%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.31%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. gallbladder mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.28%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.28%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| - | æ·å¯è¡›éŒ  | éŒ åŠ‘ | éª¨é«“çº–ç¶­åŒ–ã€çœŸæ€§ç´…è¡€çƒå¢å¤šç—‡ã€GvHD |
| - | Hydroxyurea è† å›Š | è† å›Š | æ…¢æ€§éª¨é«“æ€§ç™½è¡€ç—…ã€åµå·¢ç™Œã€é ­é ¸ç™Œ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šæ–‡ç»ä¸­å¤šèˆ‡å…¶ä»–åŒ–ç™‚è—¥ç‰©åˆä½µä½¿ç”¨
- **æ³¨æ„äº‹é …**ï¼š
  - éª¨é«“æŠ‘åˆ¶æ˜¯æœ€ä¸»è¦çš„åŠ‘é‡é™åˆ¶æ¯’æ€§
  - é•·æœŸä½¿ç”¨å¯èƒ½å¢åŠ ç¹¼ç™¼æ€§ç™½è¡€ç—…é¢¨éšª
  - çš®è†šæ¯’æ€§ï¼ˆè‰²ç´ æ²‰è‘—ã€æ½°ç˜ï¼‰
  - å·¨çƒæ€§è²§è¡€
- **ä¹³ç™Œé©ç”¨è€ƒé‡**ï¼š
  - ç›®å‰å¤šç”¨æ–¼é«˜åŠ‘é‡åŒ–ç™‚æ–¹æ¡ˆ
  - éœ€è€ƒé‡èˆ‡ç¾æœ‰æ¨™æº–æ²»ç™‚çš„æ¯”è¼ƒ

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Nervous System Diseases** ğŸ”´ Major
- Neurological symptoms such as disorientation or hallucinations have been reported very rarely during hydroxyurea therapy.  Therapy with hydroxyurea should be administered cautiously to patients with or predisposed to neurological disorders.

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- There are no data supporting specific guidance for hydroxyurea dosage adjustment in patients with hepatic impairment.  Caution and close monitoring is advised in these patients.

**ç™²ç™‡ (Epilepsy)** ğŸŸ¡ Moderate
- Seizures have been noted very rarely during hydroxyurea therapy.  Therapy with hydroxyurea should be administered cautiously in patients with seizure disorders.

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- The use of hydroxyurea is contraindicated in patients with marked myelosuppression.  Hydroxyurea induces myelosuppression, primarily leukopenia.  Thrombocytopenia and anemia occur less frequently.  Patients should be instructed to immediately report ...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¢ Minor
- Hydroxyurea is primarily eliminated by the kidney.  Approximately 80% of urea is excreted in the urine as unchanged drug or urea.  Patients with marked renal impairment (CrCl < 60 mL/min or ESRD) may be at increased risk of toxicity associated with a...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
- è±å¯Œçš„é«”å¤–ç ”ç©¶æ”¯æŒ HU åœ¨ä¹³ç™Œä¸­çš„æ´»æ€§
- å·²æœ‰ Phase I/II è‡¨åºŠç¶“é©—ï¼Œå°¤å…¶åœ¨é«˜åŠ‘é‡åŒ–ç™‚æ–¹æ¡ˆä¸­
- æ–°ç©çš„è—¥ç‰©å‚³éç³»çµ±ï¼ˆå¦‚è„‚è³ªè¤‡åˆé«”ï¼‰å¯èƒ½æ”¹å–„ç™‚æ•ˆ
- èˆ‡å…¶ä»–è—¥ç‰©çš„å”åŒä½œç”¨æä¾›è¯åˆæ²»ç™‚æ©Ÿæœƒ

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- è©•ä¼° HU åœ¨ç¾ä»£ä¹³ç™Œæ²»ç™‚ä¸­çš„è§’è‰²ï¼ˆèˆ‡ CDK4/6 æŠ‘åˆ¶åŠ‘ã€å…ç–«æ²»ç™‚çš„æ¯”è¼ƒæˆ–è¯åˆï¼‰
- é–‹ç™¼æ›´æœ‰æ•ˆçš„è—¥ç‰©å‚³éç³»çµ±ä»¥æé«˜è…«ç˜¤é¶å‘æ€§
- ç¢ºå®šæœ€é©åˆçš„ä¹³ç™Œäºå‹ï¼ˆå¦‚ä¸‰é™°æ€§ä¹³ç™Œï¼‰
- è¨­è¨ˆèˆ‡ valproic acid æˆ–å…¶ä»–å¢æ•åŠ‘çš„è¯åˆç”¨è—¥æ–¹æ¡ˆ


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Acetazolamide]({{ "/drugs/acetazolamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Vonoprazan]({{ "/drugs/vonoprazan/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Omalizumab]({{ "/drugs/omalizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Prednisone]({{ "/drugs/prednisone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Hydroxyureaè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/hydroxyurea/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_hydroxyurea,
  title = {Hydroxyureaè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/hydroxyurea/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
